recurrent prostate cancer Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Male only (1)

Unknown (1)

Interventional (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadprostate cancer

I am/have/hadcancer

I am/have/hadmetastasis

I am/have/hadbone scan

I am/have/hadadenocarcinoma

I am/have/hadct scan

I am/have/hadlocal therapy

I am/have/hadtestosterone level

I am/have/haddefinitive treatment

I am/have/hadbody mass index

I am/have/hadserum testosterone

I am/have/hadtumor progression

I am/have/hadadenocarcinoma of prostate

I am/have/haddefinitive therapy

added new label for I am/have/had

more

I am looking for

I am looking fortestosterone

I am looking forendocrine therapy

I am looking forhormone therapy

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For Seniors
For adults
Recruiting in 100s
Interventional Study
For Males
Family Medicine
Recruiting

EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

local therapy

tumor progression

metastasis

definitive treatment

cancer

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.